EGFR and head and neck squamous cell carcinoma: The epidermal growth factor receptor (EGFR) was anticipated to be a good drug target for SCCHN treatment because the majority of SCCHN overexpress EGFR [2, 3], and higher tumor levels of EGFR are associated with poorer clinical outcomes [4, 5].